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Abstract. Chagas disease, which is caused by the protozoan parasite Trypanosoma cruzi, can lead to severe cardiac
and gastrointestinal disease. Most persons acquire this infection through contact with vector bugs carrying T. cruzi in
endemic areas of Latin America. Infection can also be acquired by congenital, transfusion, transplantation, and
foodborne transmission. Although an estimated 300,000 persons with Chagas disease live in the United States, little is
known about the burden of chagasic heart disease. It is not known how often congenital or vector-borne transmission of
T. cruzi occurs in the United States, although it is known that infected mothers and infected vector bugs are found in this
country. Better diagnostic tests and treatment drugs are needed to improve patient care, and research is needed to define
transmission risks and develop strategies to prevent new infections and reduce the burden of disease.
BACKGROUND
Chagas disease is caused by the protozoan parasite
Trypanosoma cruzi and is endemic to the Americas. The
parasite causes a vector-borne zoonosis and is capable of
infecting many mammalian species, including humans. Most
human T. cruzi infections are acquired via contact with
infected triatomine bugs, when the parasite passed in tri-
atomine feces enters the body through contamination of
breaks in the skin or the conjunctiva. Vector-borne trans-
mission can also occur when food or drink is tainted by
infected triatomines or their fecal matter. Chagas disease
can also be transmitted from mother to child and through
blood transfusion and organ or tissue transplantation. An esti-
mated 100 million persons are at risk for infection; most of
these persons live in poverty in rural areas of Latin America,
and 8 million persons have Chagas disease. Approximately
12,000 deaths are attributed to Chagas disease annually.1
Chagas disease has two phases, acute and chronic. The
acute phase of infection lasts 6–8 weeks after a 1–2 week
incubation period, and is often asymptomatic. In some per-
sons, non-specific symptoms or rarely acute myocarditis or
meningoencephalitis develop; infants appear to be at higher
risk for severe manifestations.2 In the absence of treatment,
persons enter the chronic phase of infection. Most persons
will remain chronically infected and asymptomatic through-
out their lives although they are still potential sources of
transmission and at risk for reactivation of their infection if
immunosuppression occurs. This asymptomatic presentation
is the indeterminate form of chronic Chagas disease. The
transition to clinical cardiac and/or gastrointestinal disease,
the determinate form of chronic Chagas disease, happens after
years to decades in approximately 20–30% of chronically
infected persons. Progression to determinate disease may
depend on host factors, including the host’s immune response,
and parasite factors, such as strain of infecting T. cruzi.2,3 The
manifestations of determinate chronic Chagas disease are
mostly cardiac and include arrhythmias, including heart block,
heart failure, and less frequently stroke, and sudden death.
Gastrointestinal megasyndromes can also develop with or
without cardiac disease.
Acute phase Chagas disease is diagnosed by identification
of the parasite in the bloodstream by microscopic examina-
tion or hemoculture of peripheral blood; polymerase chain
reaction testing (PCR) can provide earlier and more sensitive
indication of circulating parasite but does not confirm the
presence of viable parasites because this testing method
detects only the parasite genome.4 In the chronic phase, the
parasite is found sparsely distributed intracellularly in
tissues throughout the body and rarely in the blood.
Parasitemia is not detectable by microscopy and only inter-
mittently by other more sensitive methods, such as PCR.
Chronic phase infections are diagnosed by detection of
T. cruzi-specific antibodies. The humoral immune response to
the parasite is consistently present in infected persons but
detectable antibody varies from person to person, and sero-
logic assays can have varying sensitivity possibly due to the
infecting strain of T. cruzi.5–7 No single serologic test is
suitable as a gold standard for diagnosis.7 Positive results
from testing with at least two different serologic assays of
differing formats and antigen preparations are required to
make a serologic diagnosis of infection.7,8
Two drugs (benznidazole and nifurtimox) are currently
available for treatment of Chagas disease. Both drugs are
highly effective for treatment of acute phase infections and
less so when treating chronic phase infections.2,8,9 The goal of
treatment of chronic phase infections is to reduce or stop pro-
gression of cardiac disease, which does not appear to require
parasitologic cure. Antitrypanosomal treatment is less likely
to benefit patients with gastrointestinal manifestations, which
are typically diagnosed after irreversible damage to intramu-
ral neurons has occurred.2 Benznidazole and nifurtimox are
associated with side effects that can lead to early termina-
tion of treatment, although the profile of side effects is dif-
ferent for each.9 As of 2013, neither drug has been submitted
for U.S. Food and Drug Administration (FDA) approval, but
both are available from the Centers for Disease Control and
Prevention under investigational protocols. The frequency of
side effects, lower effectiveness in chronic infections, and
logistical difficulty for physicians wishing to prescribe these
drugs create barriers to successful treatment of patients with
Chagas disease.
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As persons migrate to urban areas within countries and to
other parts of the world, Chagas disease has become a pub-
lic health concern that is not limited to rural populations
in Latin America. The United States and endemic Latin
American countries face similar challenges, including how
to increase disease awareness without increasing stigma as
a disease of the poor, how to prevent congenital transmis-
sion, and how to stop the development of severe, some-
times fatal cardiomyopathy by increasing the numbers of
infected persons receiving appropriate treatment. Better
diagnostic tools and antitrypanosomal drugs also are
needed, as well as improved access to testing and treatment.
To generate effective prevention strategies, we need data to
better understand the extent of Chagas disease in the United
States. Critical needs include assessment of transmission rate
from infected mothers to infants, quantification of the pro-
portion of non-ischemic cardiomyopathy caused by Chagas
disease, and evaluation of the risk of vector-borne transmis-
sion. In this report, we briefly outline what is known about
Chagas disease in the United States, the challenges and gaps
in public health knowledge, and suggested ways to address
those gaps.
More information on the manifestations of disease can be
found at www.cdc.gov/parasites/chagas. Continuing educa-
tion credits can be obtained through an online course found
at www.cdc.gov/parasites/cme/chagas.index.html.
PUBLIC HEALTH IMPORTANCE OF CHAGAS
DISEASE IN THE UNITED STATES
In the United States, little evidence is available to document
Chagas disease prevalence, assess congenital and vector-borne
transmission risk, and quantify the clinical disease burden.
Based on immigration estimates for the United States and prev-
alence estimates in Latin America, more than 300,000 persons
with Chagas disease are living in this country; many of these
persons do not know that they are infected.10 An estimated
63–315 babies acquire T. cruzi infection congenitally in the
United States every year but most infections go undetected
and untreated.10,11 Based on these estimates, chagasic car-
diomyopathy, which can be prevented through early treat-
ment, affects approximately 30,000–45,000 persons in the
United States.10
As of February 2013, only four states (Arizona,Massachusetts,
Tennessee, and Texas) were systematically collecting reports
of Chagas disease, and there is no national surveillance.
Some insight regarding the numbers and distribution of
persons with Chagas disease comes from blood donor screen-
ing. Although most of the nation’s blood supply has been
screened since 2007 after licensure of a screening assay,
some blood collection centers only started screening blood
donations in early 2012 after release of final FDA guidance in
late 2010.12 AABB (formerly the American Association of
Blood Banks) has collected reports of positive blood donor
testing results voluntarily submitted by member blood collec-
tion agencies to their Chagas’ Biovigilance Network. As of
February 1, 2013, 1,752 blood donors with positive screening
test and supplemental test results had been reported to
AABB (a map showing the geographic location of positive
donors by zip code of residence is available at http://www
.aabb.org/programs/biovigilance/Pages/chagas.aspx.) Blood
donors who have tested positive for Chagas disease are con-
centrated in parts of the country where Latino immigrants
typically reside.13
The potential for transmission of T. cruzi from infected
mothers to their infants is a significant concern in the United
States, and the first documented case of congenital transmis-
sion was reported in 2012.10,14 This report described an
infant born in 2010 with clinical manifestations of congeni-
tal Chagas disease, including ascites, pleural effusion, and
pericardial effusion.11 Given that most congenital infections
are asymptomatic at birth and that symptoms, when pres-
ent, are non-specific, Chagas disease in infants likely occurs
more frequently than recognized in the United States and is
under-diagnosed. The prevalence of infection among women
of child-bearing age is not known and there have been only
small-scale efforts to assess this risk. A study of women
delivering at a Houston hospital found that 10 (0.25%) of
4,000 mothers had chronic Chagas disease; 90% of the women
had been born in countries other than the United States,
most in Latin America.15 The result of this study was simi-
lar to a Houston study conducted 15 years earlier in which
11 (0.3%) of 3,765 pregnant women were found to be infected
when tested during prenatal care visits.16
An estimated 30,000–45,000 persons likely have cardiomy-
opathy caused by Chagas disease in the United States.10 Since
the mid-1960s, individual cases and small case series of car-
diomyopathy caused by Chagas disease in Latin American
immigrants have been reported but no assessment of the
overall burden of disease had been made.17,18 Two recent
studies of Latino immigrants with non-ischemic cardiomyop-
athy were conducted in New York City and Los Angeles.
In these two studies, 13% (5 of 39 patients enrolled) and
16% (15 of 93 patients enrolled) of cases were attributable
to Chagas disease.19–21 These results support the assump-
tion that Chagas disease is an important cause of cardiomy-
opathy among Latin American immigrants in the United
States. The development of heart disease may be slowed
or prevented by early antitrypanosomal treatment, making
Chagas disease a potentially preventable cause of heart dis-
ease in this population.2,8
Vector bugs, infected animals, and the parasite T. cruzi are
found in many parts of the southern half of the United States
and rare vector-borne infections acquired domestically have
been reported in humans.22 There are at least 11 species of
triatomine bugs capable of transmitting T. cruzi in the United
States, and in some areas more than 50% of triatomine bugs
were found to be infected with the parasite. These bugs are
found predominantly in areas where wildlife are common,
unlike the peridomiciliary habitat of the triatomine species
in Central and South America. Numerous animals can be
infected and serve as a reservoir including woodrats, pos-
sums, raccoons, armadillos, and skunks.23 Domestic dogs
may also become infected and manifest clinical cardiac dis-
ease; however, their role as reservoirs in the United States
is not defined.23 Only 23 human cases of domestically
acquired vector-borne Chagas disease have been reported
since 1955.22,24–30 Of these cases, six were acute infections in
five infants or young children and one adult.24,26–30 The
remaining 17 cases were asymptomatic chronic infections,
including 16 cases identified in a study of blood donors who
had tested positive for T. cruzi infection during 2006–
2010.22,25 The authors extrapolated their data to the wider
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blood donor population, estimating that one of 354,000 U.S.
blood donors might have acquired T. cruzi infection in the
United States.22 Transmission risk to humans is likely very
low and geographically restricted in the United States, and the
areas where there may be a higher risk of autochthonous
infection are not well defined.
GAPS IN CURRENT KNOWLEDGE AND FUTURE
DIRECTIONS
High-quality data are needed to help develop strategies to
minimize the health impacts of Chagas disease. As the map of
blood donor testing results suggests, persons with Chagas dis-
ease are living in many parts of the United States, although
often concentrated in certain areas. To efficiently target
interventions to control Chagas disease, detailed informa-
tion on the epidemiology of this disease is needed, including
sex and age distribution, risk history such as history of birth
or long-term residence in a country where transmission of
T. cruzi occurs, and presence of clinical manifestations. Formal
reporting at the state and local levels would assist efforts to
understand the distribution of Chagas disease but may not
provide a complete picture. Special studies are needed to
generate the evidence base to design interventions to reduce
the numbers of infected infants born every year, prevent the
progression to serious clinical manifestations, and protect
persons from vector-borne infections in the United States.
Such studies would include conducting and then evaluating
community-based screening surveys in areas with high con-
centrations of Latino immigrants to demonstrate the efficiency
of that approach to identify persons with Chagas disease who
are asymptomatically infected.
Identifying maternal infection is the critical first step to
finding those babies who should be monitored for congen-
ital infection in the first year of life. Maternal screening
should lead to appropriate treatment of the mother and
identification and treatment of infected children, reducing
the number of people at risk for progression to serious dis-
ease and further vertical transmission. Understanding the
extent and distribution of Chagas disease in women of child-
bearing age is needed to design a cost-effective strategy for
this intervention. The results of the previously mentioned
studies of high-risk pregnant women argue for larger and
more generalizable studies to develop appropriate public
health interventions.
Limited data suggest that Chagas disease may contribute to
up to 16% of non-ischemic cardiomyopathy in at risk Latino
populations in the United States, which could potentially be
prevented with early identification and treatment. Large-scale
studies are needed to assess the burden of cardiac disease,
define the population at risk, and quantify the costs associated
with unrecognized chagasic heart disease. These data would
inform cost-effective strategies to ensure that symptomatic
patients receive care appropriate for their infection and
asymptomatic patients are preemptively screened and treated
for chronic infection before serious disease develops.
A critical gap is lack of understanding of the risk of
domestic vector-borne transmission and how autochthonous
infections contribute to congenital infection and cardiac dis-
ease burden. Studies should be conducted in areas known
to have triatomines infected with T. cruzi, to define how
often autochthonous vector-borne transmission occurs and
the risk factors for infection. These studies should include
determinations of the presence and T. cruzi infection rate in
triatomine bugs and animal reservoirs within the same geo-
graphic area as an assessment of human infection risk. Con-
sideration of autochthonous vector-borne T. cruzi infection
among patients with cardiomyopathy in these same areas
will help quantify the role of these infections in the overall
Chagas disease burden. Understanding how much autoch-
thonous transmission is occurring and who is at risk are
critical to development of prevention strategies to protect
persons from vector-borne infection.
Several critical tools are needed for better recognition
and treatment of Chagas disease. Better performing diag-
nostic tests and validated rapid screening tests are needed
not only in the United States but worldwide. In the
United States, three serologic tests have been approved or
cleared by the FDA for patient diagnosis;31 as of 2013, only
one was available for purchase through U.S. distributors.
Rapid tests, which would enable bedside testing of pregnant
women at risk for chronic Chagas disease, have been studied
in some countries of Latin America but not in the United
States where the population at risk is composed of persons
from many different endemic areas who may be infected with
antigenically different strains of the parasite. As of 2013,
FDA has not reviewed any rapid tests. The frequency of
treatment drug side effects, lower drug effectiveness in
chronic infections, and logistical difficulty for physicians
wishing to prescribe drugs create barriers to successful treat-
ment of patients with Chagas disease. New drugs that are
effective, safe, and readily available are needed. Hopefully
new treatment options will become available soon as a result
of international drug development efforts.
What we can do now, even before the studies and surveys to
best inform policies and practices are conducted, is increase
awareness and knowledge of Chagas disease with health edu-
cation that is accurate and useful. Most persons with chronic
Chagas disease are unaware of their infection. Chagas disease
is known as a disease of poverty in rural Latin America, and
immigrants who have improved their family’s socioeco-
nomic status may be reluctant to accept that they are at risk
because of perceived stigma. Despite the substantial number
of infected persons in the United States, most U.S. health
care providers are not familiar with Chagas disease.32,33 This
lack of familiarity leads to under-diagnosis and under-
reporting. Health care providers must consider this diagno-
sis for their patients and request appropriate testing; lack of
awareness leads to missed opportunities to offer treatment
that may prevent congenital transmission and the develop-
ment of serious manifestations of infection in both mothers
and congenitally infected infants. Public health reporting
relies on health care provider awareness; currently many
cases of Chagas disease are only reported to state health
departments if the person donates blood and is screened for
the infection as part of routine blood safety procedures.
Increasing awareness of Chagas disease in at risk popula-
tions without increasing stigma and improving expertise in
health care providers would lead to more people with
Chagas disease being diagnosed and receiving appropriate
care and better case detection. Efforts to improve the health
of the U.S. Hispanic/Latino population should include Chagas
disease. Chagas disease should be added to the curricula at
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medical schools and to the preventive medicine agenda for
primary care practitioners.
The situation in the United States is unique compared with
that in other countries where Chagas disease is confined
to immigrants: the United States has both the largest esti-
mated number of immigrants with Chagas disease and
uncommon but documented domestic vector-borne transmis-
sion. In addition to ensuring that immigrants with Chagas
disease receive appropriate clinical management to prevent
disease progression and possible congenital transmission, we
need to better define domestic vector-borne risk to develop
the necessary prevention strategies. Although blood donor
screening and limited formal surveillance are a good start to
addressing these issues, much more must be done. Research is
needed to inform prevention strategies and address the chal-
lenges outlined here; the first step is to increase knowledge
and awareness of this disease among health care providers,
public health professionals, and the public. Successful control
of Chagas disease in the United States will be built on collab-
orations and partnerships to address these challenges.
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